VJHemOnc is committed to improving our service to you

ICML 2019 | Frontline ibrutinib-FCR for younger CLL patients: Phase II results

VJHemOnc is committed to improving our service to you

Matthew Davids

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the single-arm, multi-center, Phase II trial (NCT02251548) of ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) as an initial treatment for younger patients with chronic lymphocytic leukemia (CLL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter